Breaking Finance News

Piper Jaffray Companies downgraded Omnicell, Inc. (NASDAQ:OMCL) to Neutral in a report released today.

Piper Jaffray Companies has downgraded Omnicell, Inc. (NASDAQ:OMCL) to Neutral in a report released on Friday April 21, 2017.

Yesterday Omnicell, Inc. (NASDAQ:OMCL) traded 1.37% higher at $40.78. The company’s 50-day moving average is $39.49 and its 200-day moving average is $36.06. The last stock close price is up 13.08% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 242,928 shares of the stock were exchanged, down from an average trading volume of 281,729

See Chart Below

Omnicell, Inc. (NASDAQ:OMCL)

Omnicell, Inc. has a 52 week low of $28.76 and a 52 week high of $41.15 with a P/E ratio of 2,398.53 The company’s market cap is currently $0.

In addition to Piper Jaffray Companies reporting its target price, a total of 6 firms have reported on the stock. The consensus target price is $38.50 with 3 firms rating the stock a strong buy, 3 firms rating the stock a buy, 1 firm rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Omnicell, Inc. (NASDAQ:OMCL)

Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.